TREATMENT OF SMALL-CELL LUNG-CANCER WITH AN ALTERNATING CHEMOTHERAPY REGIMEN GIVEN AT WEEKLY INTERVALS - A SOUTHWEST ONCOLOGY GROUP PILOT-STUDY

被引:40
作者
TAYLOR, CW
CROWLEY, J
WILLIAMSON, SK
MILLER, TP
TAYLOR, SA
GIRI, TGS
STEPHENS, RL
LIVINGSTON, RB
机构
[1] SW ONCOL GRP,CTR STAT,SEATTLE,WA
[2] UNIV ARIZONA,ARIZONA CANC CTR,TUCSON,AZ 85721
[3] UNIV WASHINGTON,SEATTLE,WA 98195
[4] UNIV KANSAS,MED CTR,KANSAS CITY,KS 66103
关键词
D O I
10.1200/JCO.1990.8.11.1811
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We designed an intensive, weekly treatment regimen for patients with small-cell lung cancer (SCLC) using six of the most active chemotherapeutic agents for this disease (doxorubicin [DOX], cyclophosphamide [CTX], vincristine [VCR], etoposide [VP-16], cisplatin [CDDP], and methotrexate [MTX]). The goal of this program was to gain rapid, repetitive exposure to multiple, active drugs. Treatment was administered weekly for a total of 16 weeks. Seventy-six SCLC patients (limited disease, 34; extensive disease, 42) were treated. The overall complete plus partial response rate was 82%. Complete response rates of 47% and 38% were observed in patients with limited (LD) and extensive disease (ED), respectively. The median survivals for patients with LD and ED were 16.6 and 11.4 months, respectively. Toxicities were tolerable and were primarily hematologic. Twenty-six patients had one or more transient life-threatening toxicities, but only one patient developed a fatal toxicity. Eighty-four percent of the patients received 80% or greater of the intended protocol dosages over the entire 16-week treatment period. We conclude that this intensive, short-duration treatment regimen is at least as good as other "standard" regimens, and we are encouraged by the complete response rate and median survival in patients with ED SCLC. © 1990 by American Society of Clinical Oncology.
引用
收藏
页码:1811 / 1817
页数:7
相关论文
共 29 条
  • [21] MANTEL N, 1966, CANC CHEMOTHER REP, V50, P63
  • [22] MCCRACKEN JD, 1980, CANCER, V46, P2335
  • [23] MESSEIH AA, 1987, CANCER TREAT REP, V71, P61
  • [24] NATALE RB, 1985, SEMIN ONCOL, V12, P7
  • [25] OSTERLIND K, 1983, CANCER RES, V43, P6085
  • [26] CHEMOTHERAPY WITH OR WITHOUT RADIATION-THERAPY IN LIMITED SMALL-CELL CARCINOMA OF THE LUNG
    PERRY, MC
    EATON, WL
    PROPERT, KJ
    WARE, JH
    ZIMMER, B
    CHAHINIAN, AP
    SKARIN, A
    CAREY, RW
    KREISMAN, H
    FAULKNER, C
    COMIS, R
    GREEN, MR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (15) : 912 - 918
  • [27] EXPERIMENTAL BASIS AND CLINICAL-EXPERIENCE WITH NON-CROSS-RESISTANT COMBINATIONS IN SOLID TUMORS
    SEEBER, S
    DIMITRIADIS, K
    SCHUTTE, J
    SCHMIDT, CG
    [J]. CANCER TREATMENT REVIEWS, 1984, 11 : 55 - 61
  • [28] SIEROCKI JS, 1979, CANCER TREAT REP, V63, P1593
  • [29] PHASE-I TRIAL OF AGGRESSIVE WEEKLY CHEMOTHERAPY IN SMALL-CELL CARCINOMA OF THE LUNG
    WILLIAMSON, SK
    TAYLOR, SA
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1987, 10 (06): : 496 - 498